Press Releases
Published: November 19, 2020

Asthma Patients Maintain High Medication Adherence When Using Propeller Health to Manage Their Condition

Patients also used their rescue inhalers less often with the help of a digital health tool, according to new research

MADISON, Wisc., November 19, 2020 – Patients using Propeller Health to manage their asthma experienced a significant decline in rescue inhaler use and higher medication adherence rates compared to patients not using the platform, according to a new randomized controlled trial published in The Journal of Allergy and Clinical Immunology: In Practice by researchers from Propeller and NorthShore University HealthSystem.

The study’s treatment group maintained their high medication adherence at 68%, while the control group experienced a 17% decline in adherence over the course of the study.

In addition, Propeller users’ days without needing their rescue inhaler increased 19% in the treatment group, 13% more than in the control group.

Poor adherence to asthma medication and overuse of rescue inhalers have both been associated with increased asthma morbidity in previous research.1 Patients often overestimate their level of adherence to their clinician, leading to costly treatments that may not be appropriate or necessary to curb symptoms.2,3

“Increasing adherence and reducing rescue use are critical to improving the health and well-being of asthma patients,” said Giselle Monsaim, MD, lead author of the study and attending physician in the Departments of Medicine, Division of Pulmonary, Critical Care, Allergy and Immunology at NorthShore University HealthSystem. “We’re pleased to add to the body of research that shows digital health can play an important role in maintaining high adherence rates and increasing days without symptoms for people with asthma.”

“Digital health is particularly powerful when used in partnership with a patient’s clinician,” said David Van Sickle, CEO and co-founder of Propeller Health. “This study provides more evidence that clinician-led digital health programs can have a tremendous impact on outcomes, and that the clinician’s involvement helps to keep patients engaged, motivated and ultimately healthier.”

Details of the study

The published study features a randomized controlled trial that enrolled 100 patients with uncontrolled asthma, 25 to 65 years of age. Patients were recruited between April 2018 and 2019 from allergist and pulmonologist practices at NorthShore University HealthSystem in Chicago.

Treatment and control group participants both attached a small sensor to their controller and rescue inhalers. The treatment group received insights on their medication use in the Propeller app, including reminders to take missed or late doses and reports on their usage and possible triggers.

Clinicians had access to the treatment patients’ controller and rescue medication data. If patient utilization indicated poor adherence or worsening control, patients were contacted to address adherence and review asthma control status.

The control group’s medication use was remotely monitored, but they did not receive insights in the app or outreach from providers.

In previous clinical studies, the Propeller platform has been shown to increase asthma control by up to 63 percent4 and reduce asthma-related emergency department visits and hospitalizations by as much as 57 percent.5

1 Williams LK et al. J Allergy Clin Immunol Pract 2004
2 Adams SA et al. Am J Epidemiol 2005
3 Anderson WC et al. Ann Allergy Asthma Immunol 2019
4 Merchant RK et al. J Allergy Clin Immunol Pract 2016
5 Merchant RK et al. World Allergy Org J 2018
About Propeller Health

Propeller Health is a leading digital health company dedicated to making life better for every person with chronic respiratory disease. Propeller creates products to more effectively treat chronic respiratory disease and improve clinical outcomes for patients through connectivity, analytics, and companion digital experiences. The Propeller platform is used by patients, physicians and healthcare organizations in the United States, Europe and Asia. Propeller Health is a wholly owned subsidiary of ResMed (NYSE: RMD, ASX: RMD). For more information, visit http://www.propellerhealth.com.

You Might Also Like

Propeller Health Named a Winner of Fierce Healthcare Innovation Awards 2022

Propeller Health’s precision digital health platform wins the Clinical Information Management category of the Fierce Healthcare Innovation Awards 2022. The platform enables physicians and care teams to proactively identify at-risk patients in between routine visits and provide more timely clinical interventions.

MADISON, WI, November 15, 2022 – Propeller Health, a leader in precision digital health, today announces its platform for chronic condition management is a Fierce Healthcare Innovation Awards 2022 winner. The program showcases outstanding innovation that is driving improvements and transforming the industry. The Propeller Digital Health Platform for Chronic Condition Management (The Propeller Platform”) enables proactive clinical care by collecting objective patient data and displaying resulting insights directly within a provider’s native workflow. 

At Propeller, data itself is only the beginning – activating it is what powers patient care,” said Susa Monacelli, Propeller Health General Manager. By surfacing the data within clinicians' existing workflow through EHR integrations, we enable their treatment decisions and help identify at-risk patients. Patient self-management coupled with proactive clinician intervention helps improve clinical outcomes and, in turn, economic value for health systems, payers, and patients. Our focus is to do this across connected medications and therapies to change healthcare at scale.”

Propeller Health accelerates push towards value-based care with new digital health solutions for patients, providers and health systems

Announces integrations with multiple leading Electronic Health Record (EHR) systems, introduces a new solution to enable Remote Therapeutic Monitoring (RTM) by healthcare providers, and launches digital platform updates to enable respiratory care at home, in-clinic, and on-the-go.

MIAMI, March 7, 2022 – Propeller Health, a leader in digital health for asthma and chronic obstructive pulmonary disease (COPD), today announced three exciting updates and new solutions to bring its clinically proven, FDA-cleared platform to more patients, providers and health systems.

Integrations expand the reach of Propeller’s digital platform to more health systems
Propeller Health research shows digital health programs help improve outcomes for vulnerable and underserved populations with chronic respiratory conditions
News Announcement at HLTH 2021, Boston MA, October 18, 2021 MADISON, Wisconsin, October 18, 2021 - Propeller Health, a leader in digital health and therapeutics for asthma and chronic obstructive pulmonary disease (COPD), revealed two recent studies that showed that digital health interventions alongside appropriate care resources and tools can expand access and improve outcomes for elderly and underserved populations. Propeller’s digital health platform includes Bluetooth® connected inhaler sensors that chime medication reminders and record inhaler medication use, paired with a smartphone app that provides education and feedback to support self-management. In a study1 conducted in partnership with Desert Oasis Healthcare, Propeller evaluated the effect of digital health intervention on healthcare resource utilization and medication use in patients with COPD. 56 patients with COPD, average age 75, were enrolled by their clinical pharmacists, who received alerts through Propeller’s clinician portal whenever patients showed low controller medication adherence or high rescue inhaler use.